Overall survival and role of programmed death ligand 1 expression in patients with metastatic non-small-cell lung cancer and immunotherapy: an observational study from central Switzerland

Overall survival and role of programmed death ligand 1 expression in patients with metastatic non-small-cell lung cancer and immunotherapy: an observational study from central Switzerland

BACKGROUND: In clinical trials, therapy with immune checkpoint inhibitors has improved the survival of patients with metastatic non-small-cell lung cancer (NSCLC). These trials were important for drug approval and for defining new treatment standards but the effect of checkpoint inhibitors in patie...

Full description

Bibliographic Details
Main Authors: Valentina Allmann, Daniela Dyntar, Dirk Lehnick, Marco Dressler, Kristin Zeidler, Philipp Niederberger, Jeanne Godau, Joachim Diebold, Oliver Gautschi
Format: Article
Language:English
Published: SMW supporting association (Trägerverein Swiss Medical Weekly SMW) 2023-01-01
Series:Swiss Medical Weekly
Online Access:https://smw.ch/index.php/smw/article/view/3290

Similar Items

Similar Items